The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

We recently compiled a list of the Jim Cramer’s Top 12 Must-Watch Stocks. In this article, we are going to take a look at ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is ...

Pfizer (PFE) closed the latest trading day at $29.42, indicating a -0.83% change from the previous session's end. This move lagged the S&P 500's daily loss of 0.19%. Meanwhile, the Dow gained 0.09%, ...

We are stronger when we are all protected against respiratory diseases,” said Dr. Tomas Aragon, public health officer for ...

Flu season approaches and there's a new COVID variant. The time to act is now, or soon, according to the two largest local ...

We’re still asking people with COVID to jump through far too many hoops to get their hands on Pfizer Inc.’s Paxlovid.” ...

The hits just keep on coming for Bristol Myers Squibb staffers amid the company's cost-savings program.  | Bristol Myers ...